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Acetylation of p65 at lysine 314 is important for late
NF-kappaB-dependent gene expression
Abstract
Together, our results establish acetylation of K314 as an important regulatory modification of p65 and
subsequently of NF-kappaB-dependent gene expression.
RESEARCH ARTICLE Open Access
Acetylation of p65 at lysine 314 is important for
late NF-B-dependent gene expression
Karin M Rothgiesser, Monika Fey, Michael O Hottiger*
Abstract
Background: NF-B regulates the expression of a large number of target genes involved in the immune and
inflammatory response, apoptosis, cell proliferation, differentiation and survival. We have earlier reported that p65, a
subunit of NF-B, is acetylated in vitro and in vivo at three different lysines (K310, K314 and K315) by the histone
acetyltransferase p300.
Results: In this study, we describe that site-specific mutation of p65 at lysines 314 and 315 enhances gene
expression of a subset of NF-B target genes including Mmp10 and Mmp13. Increased gene expression was mainly
observed three hours after TNFa stimulation. Chromatin immunoprecipitation (ChIP) experiments with an antibody
raised against acetylated lysine 314 revealed that chromatin-bound p65 is indeed acetylated at lysine 314.
Conclusions: Together, our results establish acetylation of K314 as an important regulatory modification of p65
and subsequently of NF-B-dependent gene expression.
Background
The inducible transcription factor NF-B has an impor-
tant function in regulating immune and inflammatory
responses, apoptosis, cell proliferation and differentia-
tion and tumorigenesis [1-3]. NF-B is induced in
almost all cell types by different extracellular stimuli
causing the activation of an enormous array of target
genes [4]. The NF-B transcription factor family com-
prises NFKB1 (p50/p105), NFKB2 (p52/p100), p65
(RelA), c-Rel and RelB, which form homo- and heterodi-
mers. The most abundant, best-studied and “classical”
form of NF-B is a heterodimer consisting of the two
subunits p50 and p65. In most unstimulated cells, NF-
B is found as inactive transcription factor complex
through its physical association with one of the several
inhibitors of NF-B (IB) [5]. This family of IB’s
includes IBa, IBb, IBg, IBε (p105/p50, C-terminus),
p100/p52 (C-terminus), IB-R and Bcl-3. Virtually all
cell types show NF-B responses where the activity of
NF-B is specifically regulated at multiple levels [1,3,6]:
the level of protein synthesis, the existence of at least 12
different NF-B dimers, the interaction of these dimers
with specific IBs and their subcellular localization,
post-translational modification of these dimers in the
cytoplasm and the nucleus, differential accessibility of
B sites in various promoter and enhancer, differential
binding to B’s response elements due to different affi-
nities, and cell type and stimuli specific interaction with
a combination of cofactors.
NF-B is subject to a variety of post-translational
modifications (e.g., phosphorylation [7], ubiquitination
[8] or prolyl-isomerisation [9]) that modulate its activity.
Phosphorylation of the p65 subunit by the PKAc, MSK1
and PKCζ kinases enhances its interaction with the co-
activator p300/CBP and stimulates the NF-B transcrip-
tional activity [7,10-12], while dephosphorylation of p65
by the phosphatase WIP1 negatively affected the interac-
tion with p300 [13]. It has recently been shown that p65
and p50 are reversibly acetylated by p300 and PCAF
[14-16]. Chen et al. identified lysine residues (K) 218,
221 and 310 of p65 as acceptor sites for p300 acetyla-
tion. Kiernan et al. identified K122 and 123 in p65 as
acetylation sites modified by both p300 and P/CAF. A
recent report presented the TGF-b1-mediated acetyla-
tion of p65 at K221 in vitro and in vivo enhancing the
induced activation of NF-B by bacteria [17]. We
recently confirmed acetylation on K310 and provided
further evidence for acetylation of p65 on K314 and
315, two novel acetylation sites [18]. Genetic
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complementation of p65 knockout (-/-) cells with wild
type and acetylation-deficient mutants of p65 revealed
that neither shuttling, DNA binding nor the induction
of anti-apoptotic genes by TNFa was affected by acety-
lation on these residues. Micro array analysis of these
cells treated with TNFa for only 45 minutes identified
specific sets of genes differently regulated by wild type
or acetylation-deficient mutants of p65 [18]. Specific
genes were either stimulated or repressed by the acetyla-
tion-deficient mutants when compared to p65 wild type.
These results support the hypothesis that site-specific
p300-mediated acetylation of p65 regulates the specifi-
city of NF-B dependent gene expression.
Here, we extended the gene expression analysis to
three hours after TNFa stimulation and identified
genes, which are higher expressed by mutating K314
and 315. ChIP experiments with antibodies directed
against acetylated K314 revealed that this lysine is
indeed acetylated when p65 is bound to chromatin.
Together our results provide evidence that acetylation of
K314 is important for the regulation of NF-B-depen-
dent gene expression in vivo.
Results
Mutation of p65 K314/315 regulates TNFa-induced NF-
B-dependent gene expression at 3 hours
We provided earlier evidence that acetylation of p65 at
K310, 314 and 315 is important for the expression of a
defined subset of genes [18]. These earlier studies pro-
vided a first glance of the functional relevance of p65
acetylation, since gene expression was measured only
after 45 minutes of TNFa stimulation. In order to know
if the requirement for site-specific acetylation is main-
tained for the same genes after longer exposure to
TNFa, and to identify possible new genes regulated
through p65 acetylation, we decided to extend our ana-
lysis to 3 hours of stimulation. For this, we used p65
(-/-) mouse embryonic fibroblasts (MEFs) complemen-
ted with acetylation-deficient mutants, where the target
lysines for acetylation were mutated to arginines. These
cells were described and extensively characterized pre-
viously [18]. p65(-/-) cells complemented either with
wild type p65, an empty plasmid as control (pTV), the
acetylation-deficient double mutant K314/315R or the
triple mutant KTR (K310/314/315R), were stimulated by
TNFa for 3 hours and total RNA was isolated in three
independent replicates from these cells. RNA was ampli-
fied, labeled and hybridized to the Agilent Whole Mouse
Genome Array. After statistical analysis of the expres-
sion profiles, differentially expressed genes were identi-
fied (Fig. 1A-B, and Tables 1 and 2). We focused only
on genes that required p65 for their proper induction,
which were identified by comparing gene expression
profiles from wild type and pTV cells. The majority of
differentially expressed genes in KTR mutant were
strongly downregulated compared to wild type cells,
suggesting that acetylation of p65 at these residues is
also an important modification for the expression of the
extended NF-B-dependent gene expression (Fig. 1A).
In contrast, experiments with the double K314/315R
mutant revealed that the majority of genes were slightly
upregulated after 3 hours compared to wild type cells
(Fig. 1B).
Gene expression of Mmp10 and Mmp13 is enhanced
when K314/315 are mutated
We subsequently investigated the induction kinetics of
several genes by real-time RT-PCR in the complemented
cell lines stimulated by TNFa for different time points
(between 20 and 360 minutes). Selection of these genes
was based on their inducibility by TNFa, as well as their
dependency on p65 and their regulation by acetylation
of K314/315. Mmp13 and Mmp10 represented genes
that were upregulated in the micro array experiments of
K314/315R but not affected in KTR expressing cells. In
contrast, Cfb and Mpa2l represented genes that were
not affected in cells expressing K314/315R, but KTR,
suggesting that acetylation of K310 is important for
these genes. Overall, the absolute mRNA levels of
Mmp10 and Mmp13 were strongly and significantly
increased upon time (with a maximum value at 6 and 3
and hours, respectively) in cells expressing the K314/
315R mutant (Fig. 2A, B and Additional file 1: Supple-
mental Table S1), while the expression levels of Cfb and
Mpa2l were not affected in the same cells (Fig. 2C, D
and Additional file 1: Supplemental Table S1), corrobor-
ating our micro array results. Gene expression analysis
in cells expressing the KTR mutant indeed confirmed
that K310 is important for Cfb and Mpa2l, but counter-
acts the effect of K314/315R for Mmp10 or Mmp13
expression. Interestingly, the dependency on K310 acety-
lation for Cfb and Mpa2l was already observed when the
basal expression levels were analyzed (0 hour time
point).
Characterization of antibodies raised against acetylated
lysine 314 and 315 of p65
To further assess the functional relevance of p65 acetyla-
tion in vivo, we generated different antibodies raised
against the acetylated K314 or K315. All raised antibodies
recognized their specific p300-mediated acetylated resi-
dues on recombinant p65 acetylated in vitro (Fig. 3A) or
on over expressed p65 acetylated in vivo (Fig. 3B).
To confirm that endogenous p65 is indeed acetylated
at the indicated lysines, immunoprecipitation experi-
ments with the antibodies raised against acetylated
K314, K315 or against p65 were performed. The anti-
body anti-acK314 immunoprecipitated p65 only in cells
complemented with wild type p65 in a TNFa-dependent
manner (Fig. 3C). No p65 was immunoprecipitated in
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Table 1 Down- and upregulated genes in KTR cell line compared to wild type control
RefSeq RNA Gene symbol Gene name Fold
change
P-value
XR_001627 A630026L20 Hypothetical protein A630026L20 0.188 9.40E-30
NM_029000 Gvin1 GTPase, very large interferon inducible 1 0.26 8.04E-09
NM_024435 Nts Neurotensin 0.262 5.50E-10
NM_133871 Ifi44 Interferon-induced protein 44 0.282 0.001
NM_146015 Efemp1 Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 0.286 2.31E-20
NM_145153 Oas1f 2’-5’ oligoadenylate synthetase 1F 0.349 0.000045
NM_199015 D14Ertd668e DNA segment, Chr 14, ERATO Doi 668, expressed 0.368 0.000005
NM_145211 Oas1a 2’-5’ oligoadenylate synthetase 1A 0.369 0.001
NM_172603 Phf11 PHD finger protein 11 0.371 3.08E-07
NM_009099 Trim30 Tripartite motif protein 30 0.378 0.001
NM_183249 1100001G20Rik RIKEN cDNA 1100001G20 gene 0.395 8.10E-07
NM_030150 Dhx58 DEXH (Asp-Glu-X-His) box polypeptide 58 0.413 0.000006
NM_021394 Zbp1 Z-DNA binding protein 1 0.419 0.000443
NM_008690 Nfkbie Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon 0.422 0.000005
XM_001000862 I830012O16Rik RIKEN cDNA I830012O16 gene 0.422 0.002
NM_021792 Iigp1 Interferon inducible GTPase 1 0.427 0.000001
NM_194336 Mpa2l Macrophage activation 2 like 0.435 0.039
NM_007969 Expi Extracellular proteinase inhibitor 0.436 0.000025
NM_029000 Gvin1 GTPase, very large interferon inducible 1 0.438 0.000024
NM_009099 Trim30 Tripartite motif protein 30 0.454 0.000002
NM_011909 Usp18 Ubiquitin specific peptidase 18 0.458 0.002
NM_029803 Ifi27l2a Interferon, alpha-inducible protein 27 like 2A 0.46 0.000163
NM_029803 Ifi27l2a Interferon, alpha-inducible protein 27 like 2A 0.462 0.000471
NM_008200 H2-D4 Histocompatibility 2, D region locus 4 0.483 0.000006
NM_010501 Ifit3 Interferon-induced protein with tetratricopeptide repeats 3 0.488 0.000741
NM_153564 Gbp5 Guanylate binding protein 5 0.493 0.000843
NM_013606 Mx2 Myxovirus (influenza virus) resistance 2 0.509 0.000002
NM_198095 Bst2 Bone marrow stromal cell antigen 2 0.511 0.000046
NM_009318 Tapbp TAP binding protein 0.511 0.004
NM_172777 BC057170 cDNA sequence BC057170 0.519 0.000028
NM_018734 Gbp3 Guanylate binding protein 3 0.52 0.000867
NM_001001892 H2-K1 Histocompatibility 2, K1, K region 0.522 7.26E-07
NM_011579 Tgtp T-cell specific GTPase 0.522 0.000163
NM_008198 Cfb Complement factor B 0.523 0.000011
NM_010395 H2-T10 Histocompatibility 2, D region locus 1 0.527 0.000001
NM_007936 Epha4 Eph receptor A4 0.528 0.001
NM_010545 Cd74 CD74 antigen (invariant polypeptide of major histocompatibility complex, class II
antigen-associated)
0.532 2.94E-09
NM_008331 Ifit1 Interferon-induced protein with tetratricopeptide repeats 1 0.532 0.002
NM_001001892 H2-K1 Histocompatibility 2, K1, K region 0.533 5.43E-08
NM_028749 Npl N-acetylneuraminate pyruvate lyase 0.533 0.000004
NM_010380 H2-D1 Histocompatibility 2, D region locus 1 0.533 0.000007
NM_015783 Isg15 ISG15 ubiquitin-like modifier 0.534 0.008
NM_173743 2310016F22Rik RIKEN cDNA 2310016F22 gene 0.535 0.000166
NM_011314 Saa2 Serum amyloid A 2 0.536 3.53E-07
NM_008330 Ifi47 Interferon gamma inducible protein 47 0.542 0.000013
NM_172826 Dact2 Dapper homolog 2, antagonist of beta-catenin (xenopus) 0.544 0.008
NM_021384 Rsad2 Radical S-adenosyl methionine domain containing 2 0.547 0.005
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cells expressing the K314/315R or the KTR p65 mutant
(Fig. 3D), suggesting, that endogenous p65 is indeed
acetylated at K314 upon stimulation with TNFa. Unfor-
tunately, anti-acK315 was not specific enough to recog-
nize endogenous acetylation at K315.
Chromatin-associated p65 is acetylated at lysine 314
From the above selected genes only Cfb was already
described to contain a B site in its promoter [19]. We
therefore searched for putative B sites within the DNA
sequence 1 kB upstream of the transcription start site
(TSS) of the selected genes. Bioinformatic analysis iden-
tified several putative B sites in the promoters of
Mmp10 and Cfb, one site in the promoter of Mpa2l, but
none for Mmp13 (Fig. 4A). Mmp13 was thus not further
investigated. ChIP studies in p65(+/+) MEFs stimulated
with TNFa for 20 and 180 minutes revealed that p65
was recruited to the promoters of Cfb and Mpa2l in a
stimulus-dependent manner, while no enrichment was
observed in p65(-/-) MEFs (Fig. 4B). These recruitments
were promoter-specific, since p65 occupancy to promo-
ter of glucagon, a negative control, was not induced
upon TNFa stimulation. IP-10, a known NF-B target
gene with very well characterized B sites at its promo-
ter, served additionally as a positive control. Unfortu-
nately, no p65 enrichment could be observed to the B
sites of Mmp10 (data not shown), indicating that p65
would activate this gene through other B sites or other
transcription factors.
Table 2 Differentially regulated genes in K314/315R versus wild type control
RefSeq RNA Gene symbol Gene name Fold
change
P-value
NM_007377 Aatk Apoptosis-associated tyrosine kinase 2.995 7.21E-29
NM_009876 Cdkn1c Cyclin-dependent kinase inhibitor 1C (P57) 2.979 1.99E-09
NM_172119 Dio3 Deiodinase, iodothyronine type III 2.685 2.31E-07
NM_027406 Aldh1l1 Aldehyde dehydrogenase 1 family, member L1 2.39 1.35E-09
NM_008342 Igfbp2 Insulin-like growth factor binding protein 2 2.381 0.000196
NM_010942 Nsg1 Neuron specific gene family member 1 2.254 0.000001
NM_008607 Mmp13 Matrix metallopeptidase 13 2.222 4.57E-07
NM_010942 Nsg1 Neuron specific gene family member 1 2.119 0.000013
NM_028072 Sulf2 Sulfatase 2 2.1 0.000004
NM_027251 2010107G23Rik RIKEN cDNA 2010107G23 gene 2.057 1.81E-07
NM_019955 Ripk3 Receptor-interacting serine-threonine kinase 3 2.047 5.51E-10
NM_133888 Smpdl3b Sphingomyelin phosphodiesterase, acid-like 3B 2.04 8.17E-19
NM_001081421 Galntl1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 1 2.005 0.000414
NM_028072 Sulf2 Sulfatase 2 1.956 1.26E-07
NM_199252 Unc93a Unc-93 homolog A (C. elegans) 1.938 0.000978
XM_283765 5430433G21Rik RIKEN cDNA 5430433G21 gene 1.915 0.00025
NM_080563 Rnf144 Ring finger protein 144 1.83 0.006
NM_019471 Mmp10 Matrix metallopeptidase 10 1.829 0.000263
NM_009971 Csf3 Colony stimulating factor 3 (granulocyte) 1.807 0.000516
NM_029000 Gvin1 GTPase, very large interferon inducible 1 0.501 0.005
NM_009099 Trim30 Tripartite motif protein 30 0.506 0.036
AK077243 I830012O16Rik RIKEN cDNA I830012O16 gene 0.509 0.008
NM_009606 Acta1 Actin, alpha 1, skeletal muscle 0.511 4.48E-14
NM_153564 Gbp5 Guanylate binding protein 5 0.521 0.000007
NM_028872 5730559C18Rik RIKEN cDNA 5730559C18 gene 0.523 8.43E-07
List of differentially regulated genes in K314/315R versus wild type control at 3 hours TNFa stimulation analyzed by microarrays. Average values from at least
two biological replicates are shown.
Table 1: Down- and upregulated genes in KTR cell line compared to wild type control (Continued)
NM_001143689 H2-gs10 MHC class I like protein GS10 0.55 0.000007
NM_009155 Sepp1 Selenoprotein P, plasma, 1 0.552 1.58E-14
XM_126677 Dnahc17 Dynein, axonemal, heavy chain 17 3.081 2.80E-45
List of down- and upregulated genes in KTR cell line compared to wild type control after 3 hours of TNFa treatment, as measured by whole genome arrays.
Average values from at least two biological replicates are shown.
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Figure 1 Site-specific acetylation of p65 regulates the expression of distinct genes. Heat maps showing the gene expression profiles of
KTR cells (A) or K314/315R cells (B) compared to wild type control at 3 hours after TNFa stimulation using whole mouse genome arrays. Each
row represents a single gene, and each column represents a different cell line. Red or green represents up- or downregulation of genes relative
to the mean on each row, respectively. Mean data from at least two biological replicates is displayed. Only genes upregulated in wild type cells
compared to pTV control were taken into account (>2-fold, p-value < 0.05). From these genes, only the ones with significant changes in
expression levels (> 1.8-fold or < 0.556-fold, p-value < 0.05) between wild type and mutant cells are shown.
Figure 2 Confirmation of gene expression profiles by qRT-PCR. Gene induction of Mmp10 (A), Mmp13 (B), Cfb (C) and Mpa2l (D) in a TNFa-
dependent manner, as measured by real-time RT-PCR, from the following complemented cell lines: wild type (green), KTR (red), K314/315R (blue)
and pTV (grey). Samples were normalized to Rps6 and CanX expression levels, and expressed as fold increase relative to wild type unstimulated.
Two biological replicates were included. Shown are the means ± SD of three independent runs.
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Interestingly, ChIP experiments using the anti-acetyl
K314 antibodies showed that chromatin-associated p65
is indeed acetylated at K314 on all analyzed genes (Cfb,
Mpa2l and IP-10) (Fig. 4C), although the expression of
these genes was not affected by mutating K314/315 (Fig.
2C and 2D). Furthermore, the detected amount of
recruited p65, which was acetylated at K314, increased
over time (comparing values at 180 min and 20 min).
Unfortunately, the antibody raised against acetyl K315
was not able to immunoprecipitate p65 under the tested
conditions (data not shown). Together, these experi-
ments identified Mpa2l as a novel NF-B target gene
through the recruitment of p65 to its promoter and pro-
vide strong evidence that chromatin-bound p65 is
indeed acetylated at K314.
Discussion
We have previously shown that p65 acetylation plays an
important role in regulating NF-B-dependent transcrip-
tion of a subset of genes. Our current results confirm
those earlier findings by identifying new genes differen-
tially regulated in the acetylation-deficient mutants com-
pared to wild type cells. Remarkably, only a few genes
identified after 3 hours TNFa stimulation overlapped
with the genes identified in our previous study after 45
minutes TNFa stimulation (data not shown). We also
observed that TNFa does not induce NF-B activity in
the complemented MEFs as efficiently as in the parental
p65(+/+) MEFs used for ChIP (data not shown). There-
fore, although our complemented MEFs are useful to
address the role of p65 acetylation in vivo, we might have
identified only part of the genes influenced by p65 acety-
lation with the micro array screen.
Cfb was previously suggested to be a direct target of
NF-B by EMSA experiments [19]. Our ChIP assays
confirmed that p65 is recruited to Cfb promoter in a
TNFa-dependent manner in vivo and further identified
Mpa2l as a novel NF-B target gene. Although Mmp10
and Mmp13 were differentially expressed in acetylation-
deficient mutant cells compared to wild type cells, we
failed to detect p65 recruitment to those promoters.
One explanation could be that p65 is recruited to the
promoter region of these genes with a different kinetics
than the one we investigated here. Alternatively, p65
could bind to a regulatory element located far away
from the promoter to regulate transcription, as has been
Figure 3 Characterization of specific antibodies against p65 acetylated at K314 or 315. (A) Purified recombinant p65 wild type and the
acetylation-deficient mutants were incubated with recombinant p300 in the presence (+) or absence (-) of acetyl Co-A. Proteins were resolved
on SDS-PAGE and analyzed by western blot using the indicated antibodies. (B) HEK 293T cells were transfected with p65 wild type or mutants,
with (+) or without (-) p300 co-transfection. Acetylation of p65 at specific lysines was assessed by western blot using the specific antibodies. *
indicates a non-specific band. (C and D) p65 was immunprecipitated from untreated or TNFa-stimulated cells using the indicated antibodies.
Immunoprecipitated proteins were separated by 10% SDS-PAGE and subsequently analyzed by western blot using an anti-p65 antibody. *
indicates IgG-band.
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shown for several NF-B target genes [20-22]. NF-B is
known to activate the expression of many transcription
factors and their regulators [4]; consequently, a third
possibility is that p65 directly induces the expression of
a protein that regulates the expression of these genes.
Along this line, NF-B has been shown to directly acti-
vate the expression of the transcription factor Elk-1,
which in turn induces Mmp13 gene expression [23].
Interestingly, the stimulatory effect of mutating K314/
315 was lost when additionally mutating K310,
suggesting that K310 acetylation is not affected by the
lack of K314/315 acetylation, and that the modification
of K310 would counteract the effect of K314/315 at the
particular tested genes. Furthermore, the effect of
mutating K314/315 on gene expression was more
obvious after 3 hours of stimulation compared to early
time points (e.g. 20 minutes), suggesting that acetylation
of these lysines might more likely affect termination of
gene expression than its induction itself. Here, we pro-
vide for the first time evidence that endogenous,
Figure 4 Acetylated p65 is recruited to the promoter region of regulated genes upon TNFa stimulation. (A) Promoters of Cfb, Mpa2l and
Mmp10 have putative B sites. Schematic representation of putative B sites found in the indicated promoter regions. The distance in bp
relative to the transcription start site (TSS) of every putative B site is shown, as well as the sequence from the B site chosen for analysis by
ChIP. Chromatin immunoprecipitation analysis of p65 (B) or p65acetylated at K314 (C) from p65(+/+) MEFs kept unstimulated or treated with
TNFa for 20 or 180 minutes. Chromatin from p65(-/-) MEFs stimulated with TNFa for 180 minutes was used as negative control. Recruitment to
the indicated promoters was analyzed. Occupancy to IP-10 and Glucagon promoters was assessed as positive and negative control, respectively.
Samples were normalized to input chromatin and expressed as % input. The result is representative of three independent experiments. Mean
values ± SD of three independent runs are shown.
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chromatin-bound p65 is indeed acetylated at K314 upon
stimulation with TNFa. Unfortunately, acetylation of
K315 could not be confirmed due to the lack of a speci-
fic acetylation-dependent antibody that recognizes endo-
genous proteins. Interestingly, we observed acetylation
of p65 K314 at promoters of genes whose expression
was not affected by mutating K314/315 (e.g. IP-10).
Thus, it could well be that p65 is acetylated upon
recruitment of p300 at promoters of many genes, but
that the expression of only some of these genes is
affected by p65 acetylation at distinct lysines.
The observation that mutation of K314/315 increases
expression of certain genes (e.g. Mmp10 and Mmp13)
suggests that acetylation of K314 and possibly K315
might represses gene expression. A possible molecular
mechanism is that acetylated lysines at p65 create dock-
ing sites for bromodomain-containing proteins which
need to be recruited to promoters to modulate transcrip-
tion [24]. On the other hand, we can currently not
exclude that lysines 314 and/or 315 are modified by
another post-translation modification (e.g. methylation,
[25]) and that mutating these residues would thus affect
gene expression independently of acetylation. However,
provided the observed acetylation of chromatin-bound
p65 at K314, acetylation is more likely to compete with
another lysine modification, possibly resulting in cross-
talk between different modifications [25]. Indeed, a
recent study reported that these same two lysines (K314/
315) can be methylated by Set9 to induce ubiquitinyla-
tion of NF-B and subsequently terminate gene expres-
sion [26]. Thus, acetylation at K314 and possibly K315
could prevent methylation-mediated repression of target
genes and thus avoid methylation-induced termination of
p65-dependent gene expression. A direct evidence for
methylated p65 at K314/315 bound to chromatin is how-
ever still missing. Whether the same genes are regulated
by both post-translational modifications should be
further addressed. Alternatively, both post-translational
modifications might regulate distinct set of NF-B-
dependent genes and thus not influence each other.
Conclusions
Together, our results establish acetylation of K314 as an
important regulatory modification of p65 and subse-
quently of NF-B-dependent gene expression.
Methods
Tissue culture
Complemented p65(-/-) NIH 3T3 MEFs stably expres-
sing p65 wild type or the acetylation-deficient mutants
were generated by lentiviral complementation as pre-
viously described in [18]. Briefly, HEK 293T cells were
transfected with the packaging plasmid, the envelope
plasmid and pTV-myc-RelA/p65 wild type, RelA/p65 K/
R mutants or the control pTV vector. p65(-/-) MEFs
were infected with the viral supernatant and split into
selective medium (2.5 μg/ml Blasticidin) after thirty-six
hours. Expression of recombinant proteins was con-
firmed by western blot analysis. Pools of cells were used
for further analysis. They, as well as the p65(-/-) and
(+/+) parental NIH 3T3 MEFs kindly provided by A.
Beg [27], were maintained in DMEM supplemented
with 10% FCS, 100 units/ml penicillin/streptomycin
(Gibco) and non-essential amino acids (Gibco). HEK
293T cells were maintained in DMEM supplemented
with 10% FCS and 100 units/ml penicillin/streptomycin.
Plasmids
Plasmids for the mammalian overexpression of human
p65 wild type and mutants K310R, K314/315R and KTR
in HEK 293T cells were described elsewhere [18].
Briefly, pph-CMV-Km-RelA/p65 wild type, previously
described in [28], was used as template vector for the
generation of the p65 mutants by site-directed mutagen-
esis according to the QuickChange protocol (Strata-
gene). All introduced mutations were confirmed by
sequencing.
Reagents and antibodies
Human TNFa, Trichostatin A (TSA), Nicotinamide
(Nam) and acetyl-Coenzyme A (acetyl Co-A) were pur-
chased from Sigma. Recombinant mouse TNFa was
either purchased from Sigma or generated in our labora-
tory. Sodium fluoride (NaF) and beta-glycerophosphate
were obtained from Fluka. The acetyl-specific antibodies
for p65 anti-acetyl K314 (ab18727) and anti-acetyl K315
(ab19869) were generated by Abcam. The following
antibodies were purchased from Santa Cruz Biotechnol-
ogies: anti-p65 (sc-372) and anti-p300 (sc-585). The
anti-myc antibodies were either purchased from Roche
(11-667-149-001) or purified from hybridoma cells.
Generation of recombinant proteins
The recombinant proteins were expressed by baculo-
virus in Sf21 cells using either the FastBac or the Bac-
PAK systems (Clontech). His-tagged proteins were
purified over Ni2+-beads (ProBond, Invitrogen).
Micro array
Complemented cell lines p65 wild type or acetylation-
deficient mutants were starved overnight before either
left untreated or stimulated with 30 ng/ml TNFa for 3
hours. Total RNA from three biological replicates per
sample was isolated at different days using the ‘Total
RNA isolation mini kit’ (Agilent Technologies). RNA
quality was measured on the 2100 Bioanalyzer (Agilent
Technologies). Microarray experiments were performed
using ‘Whole Mouse Genome (4 × 44 K) Oligo Microar-
ray Kit’ (Agilent Technologies) and ‘One-color micro
array-based gene expression analysis’ (Agilent
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Technologies) following the manufacturer’s protocol.
Cy3-labeled cRNA was purified with the RNeasy kit
(Qiagen). Dye incorporation was assessed with the ND-
1000 Spectrophotometer (NanoDrop Technologies). Per
sample, 1.65 μg cRNA from each of the three biological
replicates was hybridized to independent arrays accord-
ing to the manufacturer’s protocol. Hybridized slides
were scanned with the Agilent DNA Microarray scanner
and quantified using the Agilent Feature Extraction soft-
ware. The data analysis was performed using ‘Rosetta
Resolver® Gene Expression Data Management and Ana-
lysis System’ (Rosetta Biosoftware). Briefly, data was pro-
cessed and normalized with default settings. Then, low-
signal genes with signal intensities < 0.1 were filtered
out. Differential expression between two conditions was
assessed based on the average ratio and significance. All
genes with expression ratios < 0.556 and >1.8, and a p-
value < 0.05 were selected to generate the tables of sig-
nificantly regulated genes. These sequence data have
been submitted to the GEO database http://www.ncbi.
nlm.nih.gov/geo under accession number GSE15196.
Gene expression by quantitative RT-PCR
Complemented MEFs were starved overnight before
treatment with 30 ng/ml recombinant TNFa for differ-
ent time points. Total RNA was isolated from at least
two biological samples at different days with the ‘Total
RNA isolation mini kit’ (Agilent Technologies). RNA
quantity was assessed with the ND-1000 Spectrophot-
ometer (NanoDrop Technologies). 2 μg RNA was subse-
quently retro-transcribed using the ‘High-capacity
cDNA reverse transcription kit’ (Applied Biosystems)
following the manufacturer’s protocol. Real-time PCR
was performed using the Rotor-Gene 3000 (Corbett Life
Science, now Qiagen) and TaqMan assays from Applied
Biosystems for the following genes: Cfb, Mpa2l, Mmp10,
Mmp13, Rps6 and CanX, according to Applied Biosys-
tems’ protocol. The last two genes were used as internal
controls to normalize for RNA input. RNA from at least
two biological replicates per sample was measured and
analyzed with REST [29]. Each experiment was run
three independent times, the mean value and ± SD was
calculated and blotted into graphs. A 2-tails, paired t-
Test was performed with the log of the values to addi-
tionally calculate the p-values.
In vitro acetylation assay
1 μg of recombinant p65 wild type or the acetylation-
deficient mutants were incubated with 500 ng recombi-
nant p300 in HAT buffer (50 mM Tris HCl pH8, 100
mM NaCl, 10% glycerol, 1 mM PMSF, 1 mM DTT, 1
μg/ml bepstatin, 1 μg/ml leupeptin, 1 μg/ml pepstatin
and 1 mM sodium butyrate) with or without addition of
150 μM acetyl-CoA. After 1 hour at 30°C, samples were
resolved on SDS-PAGE and analyzed by western blot.
Acetylation assays in cells
HEK 293T cells were transfected with expression plasmids
for p300 and either myc-tagged p65 wild type, the acetyla-
tion-deficient mutants or an empty vector, using the cal-
cium phosphate precipitation method. After 23 hours,
cells were treated with 10 ng/ml human TNFa for 30 min-
utes. Then, whole cell extracts were prepared and 40 μg
protein was analyzed by SDS-PAGE and western blot.
Immunoprecipitation
Whole cell extracts from the complemented cells
untreated or stimulated with 10 ng/ml TNFa for 40
minutes were used to immunoprecipitate p65. 750 μg of
extract were incubated with 1.5 μg of antibody for 1
hour at 4°C in Co-IP buffer (20 mM HEPES pH 7.9, 100
mM NaCl, 2.5 mM MgCl2, 0.05% NP-40, 1 mM PMSF,
1 μg/ml pepstatin, 1 μg/ml bestatin, 1 μg/ml leupeptin,
1 μM TSA, 5 mM Nam). Protein G sepharose was
added and samples were incubated for another 2 h at 4°
C. Samples were washed three times 5 minutes in Co-IP
buffer containing 100 mM NaCl before being subjected
to 10% SDS-PAGE, followed by western blot.
Chromatin Immunoprecipitation
p65(-/-) or (+/+) MEFs were stimulated with 10 ng/ml
mouse TNFa for the indicated time points and fixed
with 1% formaldehyde (Calbiochem) for 10 minutes.
After extensive washing, the plasma membrane was first
lysed with lysis buffer 1 (50 mM Tris HCl pH8, 2 mM
EDTA pH8, 0.1% NP-40, 10% glycerol, 1 mM PMSF, 0.5
mM DTT, phosphatase and HDAC inhibitors) and then
the nuclear membrane with lysis buffer 2 (50 mM Tris
HCl pH8, 5 mM EDTA pH8, 1% SDS, 1 mM PMSF, 0.5
mM DTT, phosphatase and HDAC inhibitors). Chroma-
tin fragmentation was achieved with the Bioruptor
(Diagenode). Sonified chromatin was diluted with 9
volumes of dilution buffer (50 mM Tris HCl pH8, 5
mM EDTA pH8, 0.5% NP-40, 200 mM NaCl and 1 mM
PMSF) and pre-cleared for 1 hour with Protein A Agar-
ose/salmon sperm DNA (Millipore). 1% of input was
saved and the remaining chromatin was then incubated
overnight with the specific antibodies. After 30 addi-
tional minutes of incubation with Protein A Agarose/
salmon sperm DNA, the immuno-complexes were
extensively washed with washing buffer (20 mM Tris
HCl pH8, 2 mM EDTA pH8, 1% NP-40, 0.1% SDS, 500
mM NaCl and 1 mM PMSF) and then with buffer TE
(10 mM Tris HCl pH8 and 1 mM EDTA pH8). Chro-
matin was eluted with 2% SDS in TE buffer and incu-
bated at 65°C for at least 6 hours. DNA was purified
with ‘QIAquick PCR purification kit’ (Qiagen) following
the manufacturer’s recommendations and measured
by real-time PCR using SYBR Green and the Rotor-
Gene 3000 (Corbett Life Science, now Qiagen). The
following primers were used: Mpa2l_forward
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(CAGCCCCTTTTATAGTGAGTC), Mpa2l_reverse
(TAC AAAATCCGGGAGTATTGC), Cfb_forward
(CACCTGTGAAGCAA GTCTCTCTCT), Cfb_reverse
(TTTGTGCAGCAAGGACTCTGACCT), IP-10_forward
(GCAATGCCCT CGGTTTACAG), IP-10_reverse
(GGCTGACTTTGGAGATGACTCA), Glucagon_
forward (GAGTGGGCGAGTGAAATCAT) and Gluca-
gon_reverse (TGAGCT GCGA ACAGGTGTAG) Sam-
ples were normalized to input chromatin and expressed
as % input. Each experiment was independently repeated
at least three times. Mean values ± SD of three indepen-
dent real-time PCR runs from one independent ChIP
are shown.
List of abbreviations
acetyl Co-AL: acetyl-CoenzymeA; ChIP: chromatin
immunoprecipitation; K: lysine; MEFs: mouse embryonic
fibroblasts; Nam: Nicotinamide; NF-B: nuclear factor
B; TNFa: tumor necrosis alpha; TSA: trichostatin A;
TSS: transcription start site.
Additional file 1: Gene expression analysis of Mmp10, Mmp13, Cfb
and Mpa2l with quantitative RT-PCR. The mean value of three
independent runs relative to wild type unstimulated is shown, as well as
± SD and p-values. P-values were calculated comparing data of each cell
line with wild type.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-
22-S1.DOC ]
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